Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage company focusing on precision oncology treatments, announced today that it has entered into financial agreements to potentially increase its capital.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback